Back in December we reported that Isis Pharmaceuticals initiated a Phase 1 study of ISIS-SMNRx in patients with spinal muscular atrophy (SMA).
The single-dose, dose-escalation study designed to assess the safety, tolerability and pharmacokinetic profile of the drug in children with SMA between the ages of 2-14 who are medically stable is still recruiting.
In this study, ISIS-SMNRx will be administered intrathecally as a single injection directly into the spinal fluid.
Contacts of participating hospitals in Boston, New York, Dallas and Salt Lake City can be found at ClinicalTrials.gov website.
Is this info confirmed? I was told New York was done with testing as early as in February.
ReplyDeleteClinical Trials last updated it on May 7 and it's supposed to be verified by ISIS Pharmaceuticals. Will look into it. Thank you for the information.
ReplyDeleteI also got an information about February that recruitment in NY was already closed.
ReplyDelete